Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Free light-chains and renal disorders: when small is worse.

Hutchison CA, Pratt G.

Lancet. 2010 Oct 9;376(9748):1220; author reply 1221-2. doi: 10.1016/S0140-6736(10)61873-9. No abstract available.

PMID:
20934588
2.

Free light-chains and renal disorders: when small is worse.

Craig WY, Ledue TB.

Lancet. 2010 Oct 9;376(9748):1221; author reply 1221-2. doi: 10.1016/S0140-6736(10)61874-0. No abstract available.

PMID:
20934591
3.

Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, Colby CL, Therneau TM, Clark R, Kumar SK, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV.

Lancet. 2010 May 15;375(9727):1721-8. doi: 10.1016/S0140-6736(10)60482-5. Erratum in: Lancet. 2010 Jul 31;376(9738):332.

4.

Free light-chains and renal disorders: when small is worse.

Stratta P, Airoldi A, Izzo C, Rossi D, Gaidano GL.

Lancet. 2010 Oct 9;376(9748):1221; author reply 1221-2. doi: 10.1016/S0140-6736(10)61875-2. No abstract available.

PMID:
20934589
5.

Light-chain MGUS: implications for clinical practice.

van Rhee F.

Lancet. 2010 May 15;375(9727):1670-1. doi: 10.1016/S0140-6736(10)60707-6. No abstract available.

PMID:
20472153
6.

Clinical practice. Monoclonal gammopathy of undetermined significance.

Bladé J.

N Engl J Med. 2006 Dec 28;355(26):2765-70. Review. No abstract available.

PMID:
17192542
7.

Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians.

Caers J, Vekemans MC, Bries G, Beel K, Delrieu V, Deweweire A, Demuynck H, De Prijck B, De Samblanx H, Kentos A, Meuleman N, Mineur P, Offner F, Vande Broek I, Van Droogenbroeck J, Vande Velde A, Wu KL, Delforge M, Schots R, Doyen C; Multiple Myeloma Study Group of the Belgian Hematological Society.

Ann Med. 2013 Sep;45(5-6):413-22. doi: 10.3109/07853890.2013.801562. Epub 2013 Jun 14. Review.

PMID:
23767978
8.

Diagnosis of monoclonal gammopathy of renal significance.

Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand JP, Picken MM, Herrera GA, Kastritis E, Merlini G, Roussel M, Fervenza FC, Dispenzieri A, Kyle RA, Nasr SH; International Kidney and Monoclonal Gammopathy Research Group.

Kidney Int. 2015 Apr;87(4):698-711. doi: 10.1038/ki.2014.408. Epub 2015 Jan 21. Review.

PMID:
25607108
9.

Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden.

Turesson I, Kovalchik SA, Pfeiffer RM, Kristinsson SY, Goldin LR, Drayson MT, Landgren O.

Blood. 2014 Jan 16;123(3):338-45. doi: 10.1182/blood-2013-05-505487. Epub 2013 Nov 12.

10.

Classifying ultra-high risk smoldering myeloma.

Waxman AJ, Mick R, Garfall AL, Cohen A, Vogl DT, Stadtmauer EA, Weiss BM.

Leukemia. 2015 Mar;29(3):751-3. doi: 10.1038/leu.2014.313. Epub 2014 Nov 5. No abstract available.

PMID:
25371175
11.

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M; International Myeloma Working Group.

Leukemia. 2010 Jun;24(6):1121-7. doi: 10.1038/leu.2010.60. Epub 2010 Apr 22. Review.

PMID:
20410922
12.

Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites.

Greenberg AJ, Vachon CM, Rajkumar SV.

Leukemia. 2012 Apr;26(4):609-14. doi: 10.1038/leu.2011.368. Epub 2011 Dec 23. Review.

13.
14.

Monoclonal gammopathy of undetermined significance: an update for nephrologists.

Parry HM, Pratt G, Hutchison CA.

Adv Chronic Kidney Dis. 2012 Sep;19(5):291-6. doi: 10.1053/j.ackd.2012.07.006. Review.

PMID:
22920639
15.

On the "significance" of monoclonal gammopathy of undetermined significance.

Bladé J.

Mayo Clin Proc. 2004 Jul;79(7):855-6. No abstract available.

PMID:
15244379
16.

Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.

Weiss BM, Kuehl WM.

Expert Rev Hematol. 2010 Apr;3(2):165-74. doi: 10.1586/ehm.10.13. Review.

17.

Involved/uninvolved immunoglobulin ratio identifies monoclonal gammopathy of undetermined significance patients at high risk of progression to multiple myeloma.

Espiño M, Medina S, Blanchard MJ, Villar LM.

Br J Haematol. 2014 Mar;164(5):752-5. doi: 10.1111/bjh.12679. Epub 2013 Nov 22. No abstract available.

PMID:
24261626
18.

Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.

Graziani MS, Merlini G.

Expert Rev Mol Diagn. 2014 Jan;14(1):55-66. doi: 10.1586/14737159.2014.864557. Epub 2013 Nov 28. Review.

PMID:
24308339
19.

The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

van de Donk NW, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, Hajek R, Kleber M, Ludwig H, Morgan G, Musto P, Plesner T, Sezer O, Terpos E, Waage A, Zweegman S, Einsele H, Sonneveld P, Lokhorst HM; European Myeloma Network.

Haematologica. 2014 Jun;99(6):984-96. doi: 10.3324/haematol.2013.100552. Epub 2014 Mar 21. Review.

20.

Monoclonal gammopathies of undetermined significance.

Kyle RA, Rajkumar SV.

Rev Clin Exp Hematol. 2002 Sep;6(3):225-52. Review.

PMID:
12616697
Items per page

Supplemental Content

Write to the Help Desk